NasdaqCancer immunotherapy biotech Unum Therapeutics sets terms for $75 million IPONasdaqUnum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company … Continue reading
The use of immunotherapy to treat metastatic breast cancerEurekAlert (press release)Immunotherapy has recently improved survival in metastatic breast cancer patients with breast cancer harbouring the expression of HER 2 receptor. Particularly in HER 2 … Continue reading
OncLive |
Promising Immunotherapy Approaches in AML
OncLive I think the most exciting thing is not only these novel drugs targeting immunotherapy and microenvironment coming down the pike, but I also see now that we have known active agents, and a lot of the discussion that I’ve seen at this conference is how … |
Genetic Literacy Project |
FDA puts clinical hold on Solid Biosciences’ gene therapy trial for Duchenne muscular dystrophy over toxicity concerns
Genetic Literacy Project The FDA has imposed a full clinical hold on Solid Biosciences’ Phase I/II trial for its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, the company acknowledged. GNITE DMD had been on a partial clinical hold since November … Financial Contrast: Solid Biosciences (SLDB) & Its PeersThe Ledger Gazette |
|
World’s Most Expensive Shampoo Triple Stem Cell Shampoo
PR Newswire (press release) Amazing Moisture® Shampoo contains cutting edge combination of beneficial stem cells plus the powerful healing and nourishing properties of specific botanical extracts and extremely mild coconut cleansers. All are formulated in a base of certified … |
|
MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR …
Markets Insider GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was … |
|
MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapy’s TCR …
Markets Insider GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) — Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was … |